The need for identifying standardized indices for measuring glucose variability

Journal of Diabetes Science and Technology

Volumn 6, Issue 1, 2012, Pages 218-219

  Picconi, Fabiana ^a   Di Flaviani, Alessandra ^a   Malandrucco, Ilaria ^a   Giordani, Ilaria ^a   Longo, Susanna ^a   Frontoni, Simona ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

8 iso prostaglandin F2 ; Continuous glucose monitoring; Glycemic variability; Oxidative stress

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; GLUCOSE; INSULIN DERIVATIVE; ISOPROSTANE DERIVATIVE; METFORMIN; ORAL ANTIDIABETIC AGENT;

BLOOD GLUCOSE MONITORING; GLUCOTOXICITY; GLYCEMIC CONTROL; GLYCEMIC INDEX; GLYCEMIC VARIABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOGLYCEMIA; LETTER; METABOLIC BALANCE; METABOLIC PARAMETERS; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; TANDEM MASS SPECTROMETRY; BLOOD; FEMALE; GLUCOSE BLOOD LEVEL; MALE; METABOLISM; NOTE; PHYSIOLOGY;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; OXIDATIVE STRESS;

EID: 84863593150     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681200600129     Document Type: Letter

References (6)

1. Siegelaar SE, Barwari T, Kulik W, Hoekstra JB, DeVries HJ. No relevant relationship between glucose variability and oxidative stress in well-regulated type 2 diabetes patients. J Diabetes Sci Technol. 2011;5(1):86-92.
2. Di Flaviani A, Picconi F, Di Stefano P, Giordani I, Malandrucco I, Maggio P, Palazzo P, Sgreccia F, Peraldo C, Farina F, Frajese G, Frontoni S. Impact of glycemic and blood pressure variability on surrogate measures of cardiovascular outcomes in type 2 diabetic patients. Diabetes Care. 2011;34(7):1605-9. Epub 2011 May 24.
3. Cameron FJ, Donath SM, Baghurst PA. Measuring glycaemic variation. Curr Diabetes Rev. 2010;6(1):17-26.
4. De Caterina R, Cipollone F, Filardo FP, Zimarino M, Bernini W, Lazzerini G, Bucciarelli T, Falco A, Marchesani P, Muraro R, Mezzetti A, Ciabattoni G. Low-density lipoprotein level reduction by the 3-hydroxy-3-methylglutaryl coenzyme-A inhibitor simvastatin is accompanied by a related reduction of F2-isoprostane formation in hypercholesterolemic subjects: no further efect of vitamin E. Circulation. 2002;106(20):2543-9. (Pubitemid 35340689)
5. Giaccari A, Sorice G, Muscogiuri G. Glucose toxicity: the leading actor in the pathogenesis and clinical history of type 2 diabetes - mechanisms and potentials for treatment. Nutr Metab Cardiovasc Dis. 2009;19(5):365-77. Epub 2009 May 9.
6. Proudfoot J, Barden A, Mori TA, Burke V, Croft KD, Beilin LJ, Puddey IB. Measurement of urinary F(2)-isoprostanes as markers of in vivo lipid peroxidation-A comparison of enzyme immunoassay with gas chromatography/mass spectrometry. Anal Biochem. 1999 Aug 1;272(2):209-15. (Pubitemid 29364984)